[1] |
SORIA F, SHARIAT S F, LERNER S P, et al. Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)[J]. World J Urol, 2017, 35(3): 379-387.
doi: 10.1007/s00345-016-1928-x
pmid: 27604375
|
[2] |
HE W, CHEN C H, LIN T X, et al. Epidemiology, treatments, and related biomarkers of locally advanced or metastatic urothelial carcinoma in Chinese population: a scoping review[J]. Cancer Med, 2023, 12(14): 15384-15403.
|
[3] |
GUPTA S, ANDREEV-DRAKHLIN A, FAJARDO O, et al. Platinum ineligibility and survival outcomes in patients with advanced urothelial carcinoma receiving first-line treatment[J]. J Natl Cancer Inst, 2024, 116(4): 547-554.
|
[4] |
ZINNALL U, WEYERER V, COMPÉRAT E, et al. Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype[J]. Hum Pathol, 2018, 80: 55-64.
doi: S0046-8177(18)30190-4
pmid: 29885409
|
[5] |
YOROZU T, SATO S, KIMURA T, et al. HER2 status in molecular subtypes of urothelial carcinoma of the renal pelvis and ureter[J]. Clin Genitourin Cancer, 2020, 18(4): e443-e449.
|
[6] |
WEN F, LIN T H, ZHANG P, et al. RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2-positive locally advanced muscle-invasive urothelial bladder cancer: a multi-center phase Ib/II study (HOPE-03)[J]. Front Oncol, 2023, 13: 1233196.
|
[7] |
SHENG X N, YAN X Q, WANG L, et al. Open-label, multicenter, phase II study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma[J]. Clin Cancer Res, 2021, 27(1): 43-51.
doi: 10.1158/1078-0432.CCR-20-2488
pmid: 33109737
|
[8] |
张孟尼, 龚静, 陈雪芹, 等. 尿路上皮癌429例HER2表达情况及临床病理学分析[J]. 中华病理学杂志, 2023, 52(3): 243-249.
|
|
ZHANG M N, GONG J, CHEN X Q, et al. Expression of HER2 in 429 cases of urothelial carcinoma and clinicopathological analysis[J]. Chin J Pathol, 2023, 52(3): 243-249.
|
[9] |
黎美仁, 路名芝, 郑美蓉, 等. HER2及CD44v6在膀胱尿路上皮癌中的表达及意义[J]. 中国老年学杂志, 2018, 38(19): 4641-4647.
|
|
LI M R, LU M Z, ZHENG M R, et al. Expression and significance of HER2 and CD44v6 in bladder urothelial carcinoma[J]. Chin J Gerontol, 2018, 38(19): 4641-4647.
|
[10] |
中国抗癌协会肿瘤病理专业委员会, 中国临床肿瘤学会尿路上皮癌专家委员会. 中国尿路上皮癌人表皮生长因子受体2检测临床病理专家共识[J]. 中华肿瘤杂志, 2021, 43(10): 1001-1006.
|
|
Tumor Pathology Committee of Chinese Anti-Cancer Association, Expert Committee on Urothelial Carcinoma of Chinese Society of Clinical Oncology. Clinical pathological expert consensus on HER2 testing in urothelial carcinoma in China[J]. Chin J Oncol, 2021, 43(10): 1001-1006.
|
[11] |
WANG J Y, LIU Y J, ZHANG Q Y, et al. RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: a pooled analysis of two studies[J]. J Clin Oncol, 2021, 39(15_suppl): 1022.
|
[12] |
王磊, 谢进东. HER2在膀胱尿路上皮癌中的表达及意义[J]. 右江医学, 2009, 37(4): 386-388.
|
|
WANG L, XIE J D. The expression and significance of HER2 in uroepithelium cell carcinoma of bladder[J]. Mod Chin Med, 2009, 37(4): 386-388.
|
[13] |
KHALIFA S E. Immunohistochemical expression of CD117/KIT, HER2, and Erβ in schistosomal and non-schistosomal urothelial carcinoma of Egyptian patients[J]. Int Urol Nephrol, 2023, 55(10): 2473-2481.
doi: 10.1007/s11255-023-03667-1
pmid: 37338655
|
[14] |
SCHERRER E, KANG A, BLOUDEK L M, et al. HER2 expression in urothelial carcinoma, a systematic literature review[J]. Front Oncol, 2022, 12: 1011885.
|
[15] |
黎美仁, 郑美蓉, 周燕, 等. 膀胱尿路上皮癌中HER2基因扩增及蛋白表达的意义[J]. 赣南医学院学报, 2015, 35(4): 514-517.
|
|
LI M R, ZHENG M R, ZHOU Y, et al. Gene amplification and protein expression of the human epidermal growth factor receptor 2 in urothelial carcinoma of bladder[J]. J Gannan Med Univ, 2015, 35(4): 514-517.
|
[16] |
王婧婧, 吴景, 尹恬恬, 等. HER2与膀胱尿路上皮癌临床病理分子分型的相关性[J]. 中山大学学报(医学科学版), 2020, 41(5): 758-766.
|
|
WANG J J, WU J, YIN T T, et al. Correlation of HER2 with clinicopathologic features and molecular subtypes of urothelial bladder carcinoma[J]. J Sun Yat Sen Univ Med Sci, 2020, 41(5): 758-766.
|
[17] |
管建云, 李军扩. HER2在膀胱尿路上皮细胞癌组织中的表达及其临床意义[J]. 中国当代医药, 2014, 21(24): 13-15.
|
|
GUAN J Y, LI J K. The expression and clinical significance of HER2 in bladder urothelial cell carcinoma[J]. China Mod Med, 2014, 21(24): 13-15.
|
[18] |
ZHU K J, CHANG Y, ZHAO D L, et al. Expression of HER2 in high-grade urothelial carcinoma based on Chinese expert consensus and the clinical effects of disitamab vedotin-tislelizumab combination therapy in the treatment of advanced patients[J]. Front Pharmacol, 2024, 15: 1355081.
|
[19] |
ZHOU L, SHAO Z T, LIU Y Q, et al. HER2 expression associated with clinical characteristics and prognosis of urothelial carcinoma in a Chinese population[J]. Oncologist, 2023, 28(8): e617-e624.
doi: 10.1093/oncolo/oyad070
pmid: 36971495
|
[20] |
LIN M X, LUO T, JIN Y Z, et al. HER2-low heterogeneity between primary and paired recurrent/metastatic breast cancer: Implications in treatment and prognosis[J]. Cancer, 2024, 130(6): 851-862.
|
[21] |
ALMSTEDT K, KRAUTHAUSER L, KAPPENBERG F, et al. Discordance of HER2-low between primary tumors and matched distant metastases in breast cancer[J]. Cancers, 2023, 15(5): 1413.
|